This study commissioned by the European Patent Office demonstrates the application of patent information to gain insights into specific technological fields, in this case Chimeric Antigen Receptor T-cell Immunotherapy (CAR T-cell Immunotherapy). If you are interested in finding out more about patents in the field of CAR T-cell immunotherapy, a...

To enable more and more experts to use innovative cell manufacturing technology: this is the goal of the CARAT Training Fellowship Programme. In December 2019, seven talented scientists participated in the TCT training course at the MACS Academy in Bergisch Gladbach.

Despite the potential of CAR T cell therapies, there are still significant hurdles in Europe to be overcome during their development, approval process, and reimbursement. On December 3 over hundred experts met at the invitation of BIO.NRW and Miltenyi Biotec at ATMP Workshop in Brussels to come up with solutions and make these novel therapies...

CARAT together with the EU initiative RESTORE are conducting a joint survey within our research networks to identify the most important technological, regulatory, clinical and ethical hurdles for translation of CAR T and ATMP into clinical application. The short anonymous survey includes just 12 questions and will take roughly 7 minutes to...

It seems like yesterday that the CARAT partners met for the first time at their kick-off meeting in Bergisch Gladbach, Germany, in 2016. Now, almost four years later on 4-5 November 2019, the consortium returned to the same place to conclude the project. The meeting was hosted by the coordinator Miltenyi in the impressive Kardinal Schulte Haus...

While CAR T cell therapy has been very successful in the past years with regard to hematologic malignancies, the translation to solid tumours remains a challenge. Now, the results of two trials in the US with mesothelin and claudin 18.2 targeted CAR T cells are very promising and indicate that the therapy can be successfully applied also to...

Having entered the final project year, the CARAT consortium gathered on 7-8 March, 2019 in Langen, Germany, for their 4th Progress Meeting. The meeting was hosted by Paul-Ehrlich-Institut, a German federal authority in the field of medicinal products and partner in CARAT. While the project progress was assessed extensively by the partners during...

GMP-compliant CAR T Cell Manufacturing Training Course December 9-13, 2019